



Recruiting CML Trials		Haematology Research contact details	
<p>OPTIC (Interventional)</p> <p>PI: Prof Adam Mead</p>	<p>A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase (CP) CML to Characterize the Efficacy and Safety of a Range of Doses</p> <p>Eligibility Criteria:</p> <p>Age 18 or over, CML-CP and have received at least two prior tyrosine-kinase inhibitor (TKI) therapies and have demonstrated resistance to treatment OR have documented history of presence of T3151 mutation after receiving any number of prior TKI, ECOG performance status ≤ 2 with adequate end organ function</p>	<p>Prof Adam Mead</p>	<p>Email: adam.mead@imm.ox.ac.uk Tel: 01865 222324</p>
<p>CABL001 A2301 (Interventional)</p> <p>PI: Prof Adam Mead</p>	<p>A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With CML-CP, Previously Treated With 2 or More Tyrosine Kinase Inhibitors</p> <p>Eligibility Criteria:</p> <p>Age 18 or over with a diagnosis of CML-CP, $< 15\%$ blasts in peripheral blood and bone marrow, $< 30\%$ blasts plus promyelocytes in peripheral blood and bone marrow, $< 20\%$ basophils in the peripheral blood, $\geq 50 \times 10^9/L$ platelets, No evidence of extramedullary leukemic involvement with the exception of hepatosplenomegaly, BCR-ABL ratio $\geq 1\%$ IS, Prior treatment with a minimum of 2 prior ATP-binding site TKIs, Failure or intolerance to the last previous TKI therapy</p>	<p>Research Nurse Team</p>	<p>Email: LP.haematology.RN@oxnet.nhs.uk</p>
<p>CABL001 E2201 (Interventional)</p> <p>PI: Prof Adam Mead</p>	<p>A phase 2, multi-center, open-label, randomized study of Oral asciminib added to Imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response</p> <p>Eligibility Criteria:</p> <p>Age 18 or over with a confirmed diagnosis of CML-CP ($< 15\%$ blasts in peripheral blood and bone marrow, $< 30\%$ blasts plus promyelocytes in peripheral blood and bone marrow, $< 20\%$ basophils in the peripheral blood, $\geq 100 \times 10^9/L$ platelets), $\geq 1.5 \times 10^9/L$ neutrophils, $\geq 75 \times 10^9/L$ platelets, ≥ 9 g/dl haemoglobin, with an adequate end organ function, No evidence of extramedullary leukemic involvement with the exception of hepatosplenomegaly, ≥ 24 months of Imatinib treatment, BCR-ABL ratio $> 0.01\%$ IS and $\leq 1\%$ IS</p>		
<p>INForMeD (Non-interventional)</p> <p>PI: Prof Adam Mead</p>	<p>An observational and biological research study to investigate the genetic and cellular basis of sporadic and familial myeloid disorders</p> <p>Eligibility Criteria:</p> <p>Age 2 or over, Patients under investigation for or diagnosed with a myeloid or related disorder, Patient willing to give consent to the study</p>		